At the American Diabetes Association's 85th Scientific Sessions, Dr. Athena Philis-Tsimikas presented promising Phase 3 results for efsitora alpha, a long-lasting insulin from Eli Lilly. This new insulin shows similar effectiveness to existing options like Novo Nordisk's Awiqli but lasts in the body for a week. This advancement is particularly impactful for 20-30% of type 2 diabetes patients requiring supplementary insulin, as it may simplify treatment by reducing the frequency of injections needed for blood sugar management.
The results for efsitora show it is as effective as existing insulin alternatives in controlling blood sugar, lasting for a week instead of just a day.
Dr. Athena Philis-Tsimikas highlighted that for those needing supplementary insulin, the change to efsitora could significantly improve their management of type 2 diabetes.
Collection
[
|
...
]